Moderna Inc. said the pivotal study of its experimental coronavirus vaccine began Monday, with the first subjects receiving doses. Researchers plan to enroll 30,000 people across the U.S. in the last-stage, or phase 3, trial of the Moderna vaccine candidate. Results, which government health officials said could come by November, will determine whether two doses protect against symptomatic Covid-19, and whether it should be cleared for widespread use.

Source: Wall Street Journal July 27, 2020 12:56 UTC